The ATP binding site, a target for two generations of FDA-approved ATP-competitive inhibitors for cancer treatment, involves key residues such as Thr790, Met793, and Cys797 for drug-EGFR interactions (Hossam et al., 2016). Here, EGFR is linked to cancer.